Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

Sueta, Carla A.; Chowdhury, Mridul; Boccuzzi, Stephen J.; Smith, Sidney C.; Alexander, Charles M.; Londhe, Anil; Lulla, Ash; Simpson, Ross J.

doi:10.1016/s0002-9149(99)00117-4

Cited by 237 publications

(134 citation statements)

References 20 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…8 Consistent with previous literature, our study reported that only 1 of 3 patients received lipidlowering medication. [15][16][17][18] These data suggest that there is a significant treatment gap in high-risk women. Similar to our analyses, previous studies have reported that goal attainment in individual and combined lipid levels are associated with use of lipid-lowering medications.…”

Section: Discussionmentioning

confidence: 89%

Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting

et al. 2005

View full text Add to dashboard Cite

Background-The American Heart Association (AHA) recently established evidence-based recommendations for cardiovascular disease (CVD) prevention in women, including lipid management. This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting. Methods and Results-We conducted a historical prospective cohort analysis of a 1.1-million-member, integrated, managed-care database. Eligible high-risk women were those with evidence of previous CVD or risk equivalent who had a full lipid panel available between October 1, 1999, and September 30, 2000; were naive to lipid therapy; and had a minimum of 12 months health plan eligibility preindex and postindex lipid panel. Optimal lipid levels were defined as LDL cholesterol (LDL-C) Ͻ100 mg/dL, HDL cholesterol (HDL-C) Ͼ50 mg/dL, non-HDL-C Ͻ130 mg/dL, and triglycerides Ͻ150 mg/dL. Laboratory values and lipid pharmacotherapy were assessed longitudinally over the postindex follow-up (up to 36 months). A total of 8353 high-risk women (mean age, 66Ϯ14 years) with a mean follow-up of 27Ϯ8 months were included. Only 7% attained optimal combined lipid levels initially, and this increased to 12% after 36 months. Lipid-modifying therapy was initiated in 32% of patients, including 35% of women with LDL-C Ն100 mg/dL and 15% with LDL-C Ͻ100 mg/dL. Conclusions-Among high-risk women, few attained the AHA's standards for all lipid fractions, and only one third received recommended drug therapy, highlighting significant opportunities to apply evidence-based recommendations to manage lipid abnormalities in high-risk women. (Circulation. 2005;111:488-493.)

show abstract

Section: Discussionmentioning

confidence: 89%

Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The Quality Assurance Project analyzed treatment rates in 48 586 outpatients with CHD from 140 medical practices (80% cardiology). 5 Only 39% of these patients were treated with lipid-lowering medications and only 11% were documented to have LDL-C levels Ͻ100 mg/dL. In the third National Health and Nutrition Examination Survey (NHANES III), lipid-lowering medication was used in an estimated 11% of participants with CHD.…”

mentioning

confidence: 99%

In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease

Fonarow

Ballantyne

2001

Circulation

View full text Add to dashboard Cite

“…A considerable amount of research exploring treatment gaps has been conducted in patients with CAD. [17][18][19][20][21] Research in patients with NCIS or TIA appears to demonstrate similar findings and highlights important treatment gaps among this population. Although there are considerably fewer studies by which to draw conclusions compared with the CAD literature, studies report that …”

Section: Discussionmentioning

confidence: 65%

Ambulatory Treatment Gaps in Patients with Ischemic Stroke or Transient Ischemic Attack

Olson

Lash²,

Delate³

et al. 2013

TPJ

View full text Add to dashboard Cite

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

Cited by 237 publications

References 20 publications

Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting

Opportunity for Intervention to Achieve American Heart Association Guidelines for Optimal Lipid Levels in High-Risk Women in a Managed Care Setting

In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease

Ambulatory Treatment Gaps in Patients with Ischemic Stroke or Transient Ischemic Attack

Contact Info

Product

Resources

About